Displaying 1 - 137 of 137 tests
ABL1 Kinase Domain Mutation Analysis
RT-PCR and sequencing of the BCR-ABL1 fusion transcript for qualitative detection of mutations associated with resistance to Gleevec (imatinib) and other tyrosine kinase inhibitors. Analysis includes…
|
Molecular |
ALK Mutation Analysis
Bi-directional Sanger sequencing of ALK is performed using PCR primers designed to target hotspot mutations in exons 23 and 25.
|
Molecular |
ALL Fusion Profile
Detection of gene fusion transcripts in Acute Lymphoblastic Leukemia (ALL) from ribonucleic acid (RNA). RNA is isolated from bone marrow aspirates or peripheral blood and the cDNA sequence of…
|
Molecular |
AML Reflex Panel
Routine cytogenetics with automatic addition of the NeoTYPE™ AML Prognostic Profile when cytogenetics results show intermediate risk including normal cytogenetics, +6, +8, -Y, or del(12p).
|
Molecular |
Androgen Receptor Mutation Analysis
Bi-directional Sanger sequencing of the gene Androgen Receptor is performed using PCR primers designed to target hotspot mutations in exons 4, 5 and 8.
|
Molecular |
ASXL1 Mutation Analysis
Bi-directional sequencing of the majority of exons 13 and 14 of ASXL1, corresponding to amino acids 406-1396.
|
Molecular |
ATRX Mutation Analysis
Bi-directional Sanger sequencing of ATRX is performed using PCR primers designed to target hotspot mutations in exons 8-10, 12-15, 17, 18, 21, 22, 26, 30-32, and 35.
|
Molecular |
B-Cell Gene Rearrangement
Detection of clonal IgH gene rearragements by PCR of IgH framework regions 1, 2, 3 and joining regions. In addition, Ig Kappa gene rearrangement analysis is performed using specific oligonucleotides…
|
Molecular |
BCL1 Translocation, t(11;14)
Real-time PCR for quantitative detection of t(11;14) BCL1/IgH rearrangements. Analytical sensitivity is approximately 1 tumor cell in 1000 normal cells. Positive results are reported as a ratio…
|
Molecular |
BCL2 Translocation, t(14;18)
PCR and fragment analysis for quantitative detection of IGH-BCL2 translocations associated with 70-80% of follicular lymphoma and approximately 20% of diffuse large B-cell lymphoma. Translocations…
|
Molecular |
BCR-ABL1 Non-Standard p230
Real-time RT-PCR for detection of t(9;22) BCR-ABL1 fusion transcripts that result in p230 fusion proteins. Analytical sensitivity is 1 tumor cell in 100,000 normal cells. BCR-ABL1 Standard p210, p190…
|
Molecular |
BCR-ABL1 Standard p210, p190
Real-time RT-PCR for quantitative detection of t(9;22) BCR-ABL1 fusion transcripts that result in major p210 (E13, E14) or minor p190 (E1) fusion proteins with option to add p230 detection (micro or…
|
Molecular |
Bone Marrow Failure Syndrome Panel
Testing is performed by Blueprint Genetics. The Bone Marrow Failure Syndrome Panel includes next-gen sequencing of coding regions, exon-intron boundaries, and certain non-coding variants in 128 genes…
|
Molecular |
BRAF Mutation Analysis
Bi-directional sequencing of exon 15 of the BRAF gene, which includes qualitative detection of V600 mutations E, K, D, and others, plus other significant exon 15 mutations. For solid tumors, tumor…
|
Molecular |
BRCA1 Mutation & Del/Dup Analysis
This test is performed by sequencing the entire BRCA1 gene using next-gen sequencing complemented by conventional Sanger sequencing or other molecular methodologies to detect point mutations, small…
|
Molecular |
BRCA1/2 Mutation & Del/Dup Analysis
This test is performed by sequencing the entire BRCA1 and BRCA2 genes using massive parallel sequencing complemented by conventional Sanger sequencing or other molecular methodologies to detect point…
|
Molecular |
BRCA1/2 Mutation Analysis for Tumors
BRCA1 and BRCA2 mutation analysis is performed by next-generation sequencing of all coding exons of the BRCA1 and BRCA2 genes to detect point mutations and small insertions/deletions. This test does…
|
Molecular |
BRCA2 Mutation & Del/Dup Analysis
This test is performed by sequencing the entire BRCA2 gene using next-gen sequencing complemented by conventional Sanger sequencing or other molecular methodologies to detect point mutations, small…
|
Molecular |
Breast Cancer Index® (BCI)
Breast Cancer Index (BCI) is an RT-PCR assay performed on FFPE breast tumor tissue that integrates two gene expression-based biomarkers: 1) the HOXB13:IL17BR ratio (H/I), which is associated with…
|
Molecular |
BTK Inhibitor Acquired Resistance Panel
Concurrent bi-directional sequencing of hotpost regions in the BTK and PLC-gamma-2 genes. Analysis includes the BTK mutation C481S and surrounding regions corresponding to amino acids C464 to M509…
|
Molecular |
BTK Inhibitor Primary Susceptibility Panel
Concurrent analysis of the following by bi-directional sequencing: CARD11 exons 5 and 6, CD79B exon 5 including common Y196 mutations, CXCR4 C-terminus region, and MYD88 exon 5 including the L265P…
|
Molecular |
BTK Mutation Analysis
Bi-directional sequencing to detect the C481S mutation in exon 15 and other potential mutations within the amino acid range C464 to M509. Testing is available separately or in combination with PLC-…
|
Molecular |
CALR Mutation Analysis
Bi-directional sequencing of exon 9 of the CALR (calreticulin) gene with fragment length analysis for enhanced detection of low levels of insertion/deletion mutations.Testing is approved for…
|
Molecular |
CancerTYPE ID® with reflex to NeoTYPE® Cancer Profile
CancerTYPE ID is a proprietary molecular cancer classifier used to identify unknown or unclear tumor types and subtypes in patients with metastatic cancer. When ordered through NeoGenomics,…
|
Molecular |
CEBPA Mutation Analysis
Bi-directional sequencing of the relevant coding region and fragment analysis for detection of sequence variant and internal tandem duplication mutations. The SNP genotype at rs34529039 is reported.…
|
Molecular |
Comprehensive Hereditary Cancer Panel
Testing is performed by Blueprint Genetics. The Comprehensive Hereditary Cancer Panel includes next-gen sequencing of coding regions, exon-intron boundaries, and certain non-coding variants in 146…
|
Molecular |
CSF3R Mutation Analysis
Bi-directional sequencing of exons 14 and 17 of the CSF3R gene which includes detection of the common mutation T618I (also known as T595I).
|
Molecular |
CXCR4 Mutation Analysis
Bi-directional sequencing to detect nonsense, frameshift, and other mutations encoding the C-terminus of CXCR4. Analyzed range includes detection of the C1013G mutation and spans amino acids L301 to…
|
Molecular |
DNA Fingerprinting Analysis
STR (short tandem repeat) analysis by PCR and capillary electrophoresis (fragment analysis) is used to define sample identity and to identify mixtures of two or more genotypes within a single sample…
|
Molecular |
DNMT3A Mutation Analysis
Bi-directional sequencing of exon 26, a mutation hotspot region containing R882 and other mutations. In hematological disease, testing may be performed on plamsa to increase sensitivity. For solid…
|
Molecular |
EGFR Mutation Analysis
Bi-directional sequencing of exons 18-21 of the EGFR gene for detection of EGFR-activating mutations and TKI resistance mutations (including T790M) in these exons. Tumor enrichment is performed…
|
Molecular |
EGFR T790M Germline Mutation Analysis
Bidirectional sequence analysis of EGFR exon 20 in peripheral blood for detection of T790M germline mutation. Note: Patient and physician or genetic counselor signatures on the NeoGenomics Consent…
|
Molecular |
EGFRvIII Analysis
The EGFRvIII Analysis test is a real-time quantitative RT-PCR assay that is capable of detecting the EGFRvIII mutation that results from an inframe deletion of 801 base pairs spanning exons 2-7 of…
|
Molecular |
ETV6-RUNX1 (TEL-AML1) Translocation, t(12;21)
Real-time RT-PCR for quantitative detection of the t(12;21) ETV6-RUNX1 fusion transcript (formerly called TEL-AML1). Analytical sensitivity is 1 tumor cell in 100,000 normal cells. Positive results…
|
Molecular |
FGFR CDx Molecular Analysis
FGFR CDx Molecular Analysis is a qualitative RT-PCR assay, FDA-approved for detection of four point mutations in the FGFR3 gene (p.R248C, p.S249C, p.G370C and p.Y373C) and two FGFR3 fusions (FGFR3:…
|
Molecular |
FLT3 Mutation Analysis
Detection of internal tandem duplication and exon 20 tyrosine kinase domain (TKD) mutations using fragment-length analysis and bi-directional sequencing. Positive results identify specific TKD…
|
Molecular |
HPV DNA Tissue Testing
HPV DNA Tissue Testing is peformed on FFPE tissue. It uses PCR and fragment analysis for qualitative detection and genotyping of human papillomavirus (HPV) low risk types 6/11 and high risk types 16…
|
Molecular |
HRAS Mutation Analysis
Bi-directional sequencing of HRAS exons 2 and 3 which includes sites of common activating mutations in codons 12, 13, 59 and 61.
|
Molecular |
IDH1 & IDH2 Mutation Analysis
Bi-directional sequencing of the exon 4 mutation hotspot regions in both the IDH1 and IDH2 genes. IDH1 and IDH2 are analyzed concurrently. In hematological disease, testing may be performed on plasma…
|
Molecular |
IgH Clonality/MRD by NGS
The IgH Clonality/MRD by NGS assay detects clonal populations of B-lymphocytes in a given patient sample through the analysis of the VDJ segment of the immunoglobulin heavy chain (IgH) gene. *Note -…
|
Molecular |
IgVH Mutation Analysis
RT-PCR and bi-directional sequencing of the variable region of the immunoglobulin heavy chain for detection of mutation from germline sequence. The mutated VH gene family is identified in positive…
|
Molecular |
inv(16), CBFB-MYH11 Translocation
Real-time RT-PCR for quantitative detection of the inv(16) CBFB-MYH11 fusion transcript. Positive results are reported as ratio of the amount of fusion transcript with the amount of transcript from a…
|
Molecular |
JAK2 Exon 12-14 Mutation Analysis
RT-PCR and bi-directional sequencing to detect non-V617F mutations in exons 12-14 and most of exon 15, corresponding to the majority of the JAK2 pseudokinase domain. Exon deletion mutations are…
|
Molecular |
JAK2 V617F Mutation Analysis
Qualitative detection of the V617F mutation. The rare mutation V617I is also detected. Testing is performed on plasma for increased sensitivity whenever possible. V617F testing may be ordered…
|
Molecular |
KIT (c-KIT) Mutation Analysis
Bi-directional sequencing of KIT exons 8, 9, 11, 13 and 17 for detection of activating mutations including the common mutation D816V. For solid tumors, tumor enrichment is performed before extraction…
|
Molecular |
KRAS Exon 4 Mutation Analysis
Bi-directional sequencing of exon 4 of the KRAS gene corresponding to amino acids R97 through Q150. Codon 117 and 146 mutations are detected. For solid tumors, tumor enrichment is performed before…
|
Molecular |
KRAS Mutation Analysis
Bi-directional sequencing of exons 2 and 3 of the KRAS gene. High-sensitivity sequencing is used for enhanced detection of mutations in codons 12, 13, 59, and 61. For solid tumors, tumor enrichment…
|
Molecular |
Lung NGS Fusion Profile
The Lung NGS Fusion Profile is an RNA-based next-generation sequencing panel that detects translocations and fusions of the genes ALK, NTRK1, NTRK2, NTRK3, RET and ROS1 with known and novel fusion…
|
Molecular |
Lynch Syndrome
This test is performed by sequencing the entire EPCAM, MLH1, MSH2, MSH6 and PMS2 genes using next-gen sequencing complemented by conventional Sanger sequencing or other molecular methodologies to…
|
Molecular |
MET (c-MET) Mutation Analysis
Bi-directional Sanger sequencing of MET is performed using PCR primers designed to target hotspot mutations in exons 14, 16, 17 and 19.
|
Molecular |
MET Exon 14 Deletion Analysis
MET Exon 14 Deletion Analysis is performed by real-time RT-PCR. The assay is designed to detect alternative splice junctions that lead to exon-skipping (deletion) of exon 14 of the gene MET. Note:…
|
Molecular |
MGMT Promoter Methylation Analysis
Bisulfite modification of tumor DNA and real-time PCR are used to quantify CpG methylation within the MGMT gene promoter. Percentage of methylated DNA (compared to total DNA) is reported for positive…
|
Molecular |
Microsatellite Instability Analysis (MSI)
PCR and fragment analysis of paired normal and tumor tissue to determine microsatellite instability (MSI) at the standard five NCI-recommended loci. Positive results are reported as MSI-high (at…
|
Molecular |
MLH1 Mutation & Del/Dup Analysis
This test is performed by sequencing the entire MLH1 gene using next-gen sequencing complemented by conventional Sanger sequencing or other molecular methodologies to detect point mutations, small…
|
Molecular |
MLH1 Promoter Methylation Analysis
This assay is performed on tumor tissue to detect hypermethylation of the MLH1 gene promoter. Bisulfite modification of tumor DNA and real-time PCR are used to quantify CpG methylation within the…
|
Molecular |
MPL Mutation Analysis
Bi-directional sequencing of exon 10 of the MPL gene to detect all possible mutations at the W515 and S505 codons, and other mutations throughout the exon. Testing is performed on plasma for…
|
Molecular |
MPN Extended Reflex Panel
Sequential testing panel including qualitative detection of JAK2 V617F, JAK2 Exon 12-14, CALR exon 9, and MPL exon 10. Testing proceeds by reflex through the four-step panel until a mutation is…
|
Molecular |
MSH2 Mutation & Del/Dup Analysis
This test is performed by sequencing the entire MSH2 gene using next-gen sequencing complemented by conventional Sanger sequencing or other molecular methodologies to detect point mutations, small…
|
Molecular |
MSH6 Mutation & Del/Dup Analysis
This test is performed by sequencing the entire MSH6 gene using next-gen sequencing complemented by conventional Sanger sequencing or other molecular methodologies to detect point mutations, small…
|
Molecular |
MYD88 Mutation Analysis
Bi-directional sequencing of exon 5 of the MYD88 gene which includes detection of the common L265P mutation. Testing is approved for specimens from the state of New York.
|
Molecular |
NeoARRAY™ SNP/Cytogenetic Profile
The NeoARRAY SNP/Cytogenetic Profile is available for hematological, solid tumor, and pregnancy loss indications. With the best genome-wide coverage available, this test employs an enhanced SNP…
|
Molecular |
NeoLAB™ AML Profile - Liquid Biopsy
This test is performed by sequencing the entire coding regions of the genes listed using cell-free plasma DNA/RNA. ASXL1, BCOR, BRAF, CEBPA, CSF3R, DNMT3A, ETV6, EZH2, FLT3, HRAS, IDH1, IDH2, JAK2…
|
Molecular |
NeoLAB™ BTK Inhibitor Acquired Resistance Panel - Liquid Biopsy
The NeoLAB™ BTK Inhibitor Acquired Resistance Panel is a blood test performed by modified properietary bi-directional sequencing of the BTK and PLC-gamma-2 genes using cell-free circulating tumor DNA…
|
Molecular |
NeoLAB™ FLT3 Mutation Analysis - Liquid Biopsy
Detection of internal tandem duplication and exon 20 tyrosine kinase domain (TKD) mutations using bidirectional sequencing. Positive results identify specific TKD mutations or report ITD results…
|
Molecular |
NeoLAB™ IDH1 Mutation Analysis - Liquid Biopsy
Bi-directional sequencing of the exon 4 mutation hotspot region in the IDH1 gene. Testing is performed on cell-free plasma DNA/RNA to increase sensitivity.
|
Molecular |
NeoLAB™ IDH2 Mutation Analysis - Liquid Biopsy
Bi-directional sequencing of the exon 4 mutation hotspot region in the IDH2 gene. Testing is performed on cell-free plasma DNA/RNA to increase sensitivity.
|
Molecular |
NeoLAB™ inv(16), CBFB-MYH11 Translocation - Liquid Biopsy
Real-time RT-PCR for quantitative detection of the inv(16) CBFB-MYH11 fusion transcript using cell-free plasma DNA/RNA. This assay identifies type A fusions, which account for >90%
|
Molecular |
NeoLAB™ KIT (c-KIT) Mutation Analysis - Liquid Biopsy
Bi-directional sequencing of KIT exons 8, 9, 11, 13 and 17 for detection of activating mutations including the common mutation D816V. Testing is performed on cell-free plasma DNA/RNA to increase…
|
Molecular |
NeoLAB™ KRAS Mutation Analysis - Liquid Biopsy
Bi-directional sequencing of exons 2 and 3 of the KRAS gene. High-sensitivity sequencing is used for enhanced detection of mutations in codons 12, 13, 59, and 61. Testing is performed on cell-free…
|
Molecular |
NeoLAB™ MDS/CMML Profile - Liquid Biopsy
This test is performed by the sequencing the entire coding regions of the genes listed using cell-free plasma DNA/RNA. ASXL1, BCOR, BCORL1, BRAF, CBL, CEBPA, CUX1, DNMT3A, ETV6, EZH2, FLT3, HRAS,…
|
Molecular |
NeoLAB™ Myeloid Disorders Profile - Liquid Biopsy
This test is performed on cell-free DNA/RNA in peripheral blood plasma by sequencing the entire coding regions of the genes listed. ABL1, ASXL1, ATRX, BCOR, BCORL1, BRAF, CALR, CBL, CBLB, CBLC,…
|
Molecular |
NeoLAB™ NPM1 Mutation Analysis - Liquid Biopsy
PCR and fragment analysis of exon 12 of the NPM1 gene to detect small insertion mutations specific to AML. Positive results are reported quantitatively as percent abnormal DNA. Testing is performed…
|
Molecular |
NeoLAB™ NRAS Mutation Analysis - Liquid Biopsy
Bi-directional sequencing of NRAS exons 2 and 3 which includes sites of common activating mutations in codons 12, 13, 59, and 61. Testing is performed on cell-free plasma DNA/RNA to increase…
|
Molecular |
NeoLAB™ PML-RARA Translocation, t(15;17) - Liquid Biopsy
Real-time RT-PCR for quantitative detection of the t(15;17) PML-RARA fusion transcript using cell-free plasma DNA/RNA. Both long and short isoforms of the fusion transcript are detected.
|
Molecular |
NeoLAB™ RUNX1-RUNX1T1 (AML1-ETO) Translocation, t(8;21) - Liquid Biopsy
Real-time RT-PCR for quantitative detection of the t(8;21) RUNX1-RUNX1T1 fusion transcript (formerly called AML1-ETO) using cell-free plasma DNA/RNA.
|
Molecular |
NeoTYPE AITL/Peripheral T-Cell Lymphoma Profile
The NeoTYPE AITL/Peripheral T-Cell Lymphoma Profile is performed by the sequencing of select exons in the genes BCL1 (CCND1), IDH1, IDH2, DNMT3A, TET2 and RHOA
|
Molecular |
NeoTYPE AML Favorable-Risk Profile
This test is performed by sequencing of select exons of the genes FLT3 and KIT. Test orders include summary interpretation of all results together. Individual genes from a validated list of myeloid…
|
Molecular |
NeoTYPE® AML Prognostic Profile
This test is performed by sequencing the entire coding regions of the genes listed. ASXL1, BCOR, BRAF, CEBPA, CSF3R, DNMT3A, ETV6, EZH2, FLT3, HRAS, IDH1, IDH2, JAK2 including V617F and Exons 12+14,…
|
Molecular |
NeoTYPE® Brain Tumor Profile
The NeoTYPE Brain Tumor Profile analyzes 61 biomarkers through a combination of next-generation sequencing (NGS), other molecular methods, FISH, and IHC as listed below. Test orders include summary…
|
Molecular |
NeoTYPE® Breast Tumor Profile
The NeoTYPE Breast Tumor Profile analyzes 60 biomarkers through a combination of next-generation sequencing (NGS), FISH, and IHC as listed below. Test orders include summary interpretation of all…
|
Molecular |
NeoTYPE® Cervical Tumor Profile
The NeoTYPE Cervical Tumor Profile analyzes 43 biomarkers through a combination of next-generation sequencing (NGS), FISH, and IHC as listed below. Test orders include summary interpretation of all…
|
Molecular |
NeoTYPE® CLL Prognostic Profile
This test is performed by sequencing the entire coding regions of the genes ATM, BIRC3, BTK, CARD11, CD79B, CXCR4, MYD88, NOTCH1, SF3B1, TP53, plus IgVH Mutation Analysis and the CLL FISH Panel as…
|
Molecular |
NeoTYPE® Gastric Tumor Profile
The NeoTYPE Gastric Tumor Profile analyzes 39 biomarkers through a combination of next-generation sequencing (NGS), FISH, and IHC as listed below. Test orders include summary interpretation of all…
|
Molecular |
NeoTYPE® GI Predictive Profile
The NeoTYPE GI Predictive Profile analyzes 10 biomarkers through a combination of next-generation sequencing (NGS), FISH, and IHC as listed below. Test orders include summary interpretation of all…
|
Molecular |
NeoTYPE® HRD+ Profile
The NeoTYPE HRD+ Profile analyzes 30 genes by next-generation sequencing (NGS) as listed below.
NGS (30 genes): ATM, ATR, BARD1, BRCA1, BRCA2, BRIP1, CDK12, CHEK1, CHEK2, FANCA, FANCC, FANCD2, FANCE…
|
Molecular |
NeoTYPE® JMML Profile
This test is performed by sequencing the entire coding regions of the genes listed. BRAF, CBL, CEBPA, FLT3, HRAS, JAK2 including V617F and Exons 12+14, JAK3, KIT, KRAS, NPM1, NRAS, PDGFRA, PTEN,…
|
Molecular |
NeoTYPE Liposarcoma Fusion Profile
The NeoTYPE Liposarcoma Fusion Profile combines next-generation sequencing to detect translocations in the genes EWSR1, FUS, HMGA2, and PLAG1 with FISH testing for MDM2 to detect amplifications…
|
Molecular |
NeoTYPE® Lung Tumor Profile
The NeoTYPE Lung Tumor Profile analyzes 46 biomarkers through a combination of next-generation sequencing (NGS), other molecular methods, FISH, and IHC as listed below. Test orders include summary…
|
Molecular |
NeoTYPE® Lymphoma Profile
This test is performed by multiple methods to detect mutations in the following genes BCL1, BCL2, BCL6, BRAF, CARD11, CD79B, EZH2, MYD88, NOTCH1, NOTCH2, NRAS and TP53. The test is performed by…
|
Molecular |
NeoTYPE® MDS/CMML Profile
This test is performed by sequencing the entire coding regions of the genes listed unless another method is noted. ASXL1, BCOR, BCORL1, BRAF, CBL, CEBPA, CUX1, DNMT3A, ETV6, EZH2, FLT3, HRAS, IDH1,…
|
Molecular |
NeoTYPE® Melanoma Profile
The NeoTYPE Melanoma Tumor Profile analyzes 28 biomarkers through a combination of next-generation sequencing (NGS), FISH, and IHC as listed below. Test orders include summary interpretation of all…
|
Molecular |
NeoTYPE® Ovarian Tumor Profile
The NeoTYPE Ovarian Tumor Profile analyzes 68 biomarkers through a combination of next-generation sequencing (NGS), FISH, and IHC as listed below. Test orders include summary interpretation of all…
|
Molecular |
NeoTYPE® Pancreas Tumor Profile
The NeoTYPE Pancreas Tumor Profile analyzes 69 biomarkers through a combination of next-generation sequencing (NGS), FISH, and IHC as listed below. Test orders include summary interpretation of all…
|
Molecular |
NeoTYPE® Thyroid Profile
The NeoTYPE Thyroid Tumor Profile analyzes 32 biomarkers through a combination of next-generation sequencing (NGS), FISH, and IHC as listed below. Test orders include summary interpretation of all…
|
Molecular |
NeoTYPE® Colorectal Tumor Profile
The NeoTYPE Colorectal Tumor Profile analyzes 44 biomarkers through a combination of next-generation sequencing (NGS), other molecular methods, FISH, and IHC as listed below. Test orders include…
|
Molecular |
NeoTYPE® Discovery Profile for Solid Tumors
The NeoTYPE Discovery Profile analyzes 336 biomarkers through a combination of next-generation sequencing (NGS), FISH, and IHC as listed below. Test orders include summary interpretation of all…
|
Molecular |
NeoTYPE® Endometrial Tumor Profile
The NeoTYPE Endometrial Tumor Profile analyzes 38 biomarkers through a combination of next-generation sequencing (NGS), FISH, and IHC as listed below. Test orders include summary interpretation of…
|
Molecular |
NeoTYPE® Esophageal Tumor Profile
The NeoTYPE Esophageal Tumor Profile analyzes 38 biomarkers through a combination of next-generation sequencing (NGS), FISH, and IHC as listed below. Test orders include summary interpretation of all…
|
Molecular |
NeoTYPE® GIST and Soft Tissue Tumor Profile
The NeoTYPE GIST/Soft Tissue Tumor Profile analyzes 43 biomarkers through a combination of next-generation sequencing (NGS), FISH, and IHC as listed below. Test orders include summary interpretation…
|
Molecular |
NeoTYPE® Head & Neck Tumor Profile
The NeoTYPE Head & Neck Tumor Profile analyzes 34 biomarkers through a combination of next-generation sequencing (NGS), other molecular methods, FISH, and IHC as listed below. Test orders include…
|
Molecular |
NeoTYPE® Liver/Biliary Tumor Profile
The NeoTYPE Liver/Biliary Tumor Profile analyzes 38 biomarkers through a combination of next-generation sequencing (NGS), FISH, and IHC as listed below. Test orders include summary interpretation of…
|
Molecular |
NeoTYPE® Myeloid Disorders Profile
This test is performed by the sequencing the entire coding regions of the genes listed. ABL1, ASXL1, ATRX, BCOR, BCORL1, BRAF, CALR, CBL, CBLB, CBLC, CDKN2A, CEBPA, CSF3R, CUX1, DNMT3A, ETV6, EZH2,…
|
Molecular |
NeoTYPE® Other Solid Tumor Profile
The NeoTYPE Other Solid Tumor Profile analyzes 30 biomarkers through a combination of next-generation sequencing (NGS), FISH, and IHC as listed below. Test orders include summary interpretation of…
|
Molecular |
NeoTYPE® Precision Profile for Solid Tumors
The NeoTYPE Precision Profile analyzes 83 biomarkers through a combination of next-generation sequencing (NGS) and IHC as listed below. Test orders include summary interpretation of all results to…
|
Molecular |
NGS Comprehensive Sarcoma Fusion Profile
The NGS Comprehensive Sarcoma Fusion Profile is a targeted next-generation sequencing panel that can detect 134 different translocations relevant in sarcomas in the genes ALK, CAMTA1, CCNB3, CIC,…
|
Molecular |
NGS Ewing Sarcoma Fusion Profile
The NGS Ewing Fusion Profile is a targeted next-generation sequencing panel that can detect various translocations relevant in Ewing's sarcoma in the gene EWSR1.
|
Molecular |
NGS Non-Ewing Sarcoma Fusion Profile
The NGS Non-Ewing Sarcoma Fusion Profile is a targeted next-generation sequencing panel that can detect various translocations unrelated to Ewing's sarcoma in the genes ALK, CAMTA1, CCNB3, CIC, EPC1…
|
Molecular |
NGS Pediatric Sarcoma Fusion Profile
The NGS Pediatric Sarcoma Fusion Profile is a targeted next-generation sequencing panel that can detect various translocations related to pediatric sarcomas in the genes ALK, EWSR1, FUS, GLI1, NTRK3…
|
Molecular |
NGS Rhabdomyosarcoma Fusion Profile
The NGS Rhabdomyosarcoma Fusion Profile is a targeted next-generation sequencing panel that can detect various translocations related to rhabdomyosarcoma in the genes FOXO1, NCOA2, and TFE3.
|
Molecular |
NOTCH1 Mutation Analysis
Bi-directional sequencing of exons 26, 27, and 34 is performed for detection of sequence variant mutations. Testing can be performed on plasma when adequate leukemic cells are not available.
|
Molecular |
NPM1 MRD Analysis
NPM1 MRD Analysis is performed by PCR and fragment analysis of exon 12 of the NPM1 gene to detect small insertion mutations. Testing is performed on plasma with a PCR modification to improve…
|
Molecular |
NPM1 Mutation Analysis
PCR and fragment analysis of exon 12 of the NPM1 gene to detect small insertion mutations specific to AML. Positive results are reported quantitatively as percent abnormal DNA. Testing may be…
|
Molecular |
NRAS Exon 4 Mutation Analysis
Bi-directional sequencing of NRAS exon 4 is performed using PCR primers designed to target hotspot mutations in codons 117 and 146, among other regions in exon 4. Testing is available separately or…
|
Molecular |
NRAS Mutation Analysis
Bi-directional sequencing of NRAS exons 2 and 3 which includes sites of common activating mutations in codons 12, 13, 59, and 61. Testing is approved for specimens from the state of New York.
|
Molecular |
NTRK NGS Fusion Profile
The NTRK NGS Fusion Profile is an RNA-based next-generation sequencing panel that detects translocations and fusions of the Neurotrophic Tropomyosin-Related Kinase (NTRK) genes NTRK1, NTRK2, and…
|
Molecular |
NTRK & RET NGS Fusion Profile
The NTRK & RET NGS Fusion Profile is an RNA-based next-generation sequencing panel that detects translocations and fusions of the genes NTRK1, NTRK2, NTRK3 and RET with known and novel fusion…
|
Molecular |
Oncomine™ Dx Target Test
The Oncomine Dx Target Test is a next-gen sequencing assay designed to detect variants in 23 genes associated with non-small cell lung cancer (NSCLC). Abnormalities targeted are ROS1 gene fusions and…
|
Molecular |
PDGFRa Mutation Analysis
Bi-directional sequencing of exons 12 and 18 of the PDGFRA (platelet-derived growth factor alpha) gene. These exons are mutation hotspots that account for the majority of PDGFRA mutations detected in…
|
Molecular |
PIK3CA CDx Mutation Analysis by PCR
PIK3CA CDx Mutation Analysis by PCR is an FDA-approved qualitative companion diagnostic assay performed on DNA extracted from FFPE breast tissue to detect 11 mutations in exons 7, 9, and 20 of the…
|
Molecular |
PIK3CA LDT Mutation Analysis by Sequencing
Bi-directional sequencing of PIK3CA exons 1, 9, and 20 which are the most commonly-mutated regions of the gene.
|
Molecular |
PLC-Gamma-2 Mutation Analysis
Bi-directional sequencing to detect mutations in exons 19, 20, and 24, covering amino acid ranges W646 to S679, A681 to M743, and I839 to V860. Testing is available separately or in combination with…
|
Molecular |
PML-RARA Translocation, t(15;17)
Real-time RT-PCR for quantitative detection of the t(15;17) PML-RARA fusion transcript. Both long and short isoforms of the fusion transcript are detected. Positive results identify the isoform and…
|
Molecular |
PMS2 Mutation & Del/Dup Analysis
This test is performed by sequencing the entire PMS2 gene using next-gen sequencing complemented by conventional Sanger sequencing or other molecular methodologies to detect point mutations, small…
|
Molecular |
Prosigna® Assay
The Prosigna Assay measures tumor expression levels of 50 genes used in the PAM50 classification algorithm, weighted together with clinical variables, to predict the risk of distant breast cancer…
|
Molecular |
PTPN11 Mutation Analysis
Bi-directional sequencing of exons 2-4 of PTPN11.
|
Molecular |
RAS/RAF Panel
The RAS/RAF Panel is an NGS-based assay performed by sequencing the entire coding region (full gene) of BRAF, HRAS, KRAS and NRAS genes. The panel reports mutations detected in the full gene…
|
Molecular |
RHOA Mutation Analysis
Bi-directional sequencing of the gene RHOA. The locked nucleic acid (LNA) technique is used to increase detection sensitivity for the G17V mutation. Note - Available as stand-alone or as part of the…
|
Molecular |
RUNX1-RUNX1T1 (AML1-ETO) Translocation, t(8;21)
Real-time RT-PCR for quantitative detection of the t(8;21) RUNX1-RUNX1T1 fusion transcript (formerly called AML1-ETO). Analytical sensitivity is 1 tumor cell in 100,000 normal cells. Positive results…
|
Molecular |
SF3B1 Mutation Analysis
RT-PCR and bi-directional sequencing of exons 14-17 of the SF3B1 gene. More than 90% of reported mutations are detected in these exons. This test detects mutations present at 10-15% or more in a wild…
|
Molecular |
SRSF2 Mutation Analysis
Bi-directional sequencing of the mutation hotspot region in exon 1 of the SRSF2 gene corresponding to amino acids 57-120.
|
Molecular |
STAT3 Mutation Analysis
Bi-directional sequencing of STAT3 exons 13-21 encompassing the DNA binding and SH2 domains.
|
Molecular |
T-Cell Receptor Beta Gene Rearrangement
This test provides qualitative detection of monoclonal T-cell receptor (TCR) beta gene rearrangements by PCR and fragment analysis according to BIOMED-2 consensus primer design. This test may be…
|
Molecular |
T-Cell Receptor Gamma Gene Rearrangement
Detection of clonal T-cell receptor gamma (TCRG) gene rearrangements by PCR of variable and joining regions. T-Cell Receptor Beta Gene Rearrangement is offered separately and may be added to this…
|
Molecular |
TERT Promoter Mutation Analysis
Bi-directional Sanger sequencing is performed using PCR primers designed to target mutations in the promoter region of TERT.
|
Molecular |
TET2 Mutation Analysis
Bi-directional sequencing of the entire coding sequence of the TET2 transcript variant A (2002 amino acids in length).
|
Molecular |
TP53 Mutation Analysis
Bi-directional sequencing of TP53 exons 4-9.
|
Molecular |
UGT1A1 Genotyping
Lengths of the TA repeat polymorphism in the promoter region of the UTG1A1 gene are determined by fragment analysis using capillary electrophoresis. The alleles detected include the common normal…
|
Molecular |